- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.05. | Bristol Myers Squibb's injectable Opdivo formulation granted MHRA for solid tumours | ||
| 06.05. | Alnylam's RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease | ||
| 02.05. | Johnson & Johnson's Imaavy granted FDA approval for rare autoimmune disease gMG | ||
| 02.05. | NHS patients to access Theramex's endometriosis pill following NICE recommendation | ||
| 02.05. | AstraZeneca's triple-combination COPD therapy shows promise in uncontrolled asthma | ||
| 01.05. | Novartis to expand renal disease pipeline with $1.7bn Regulus acquisition | ||
| 01.05. | FDA approves Abeona's epidermolysis bullosa gene therapy Zevaskyn | ||
| 01.05. | UK government's AMR study highlights importance of appropriate antibiotic use | ||
| 01.05. | IPG Health announces evolution of medical communications offering | ||
| 01.05. | Medical remote monitoring: a revolution driven by connected patches | ||
| 30.04. | Eli Lilly and Creyon Bio enter oligonucleotide therapy partnership worth over $1bn | ||
| 30.04. | AbbVie's JAK inhibitor Rinvoq granted FDA approval to treat giant cell arteritis | ||
| 30.04. | AstraZeneca's Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia | ||
| 30.04. | Mastering pharma capability development cogs | ||
| 29.04. | Regeneron's bispecific antibody Lynozyfic approved by EC to treat multiple myeloma | ||
| 29.04. | MHRA approves Autolus Therapeutics' Aucatzyl to treat acute lymphoblastic leukaemia | ||
| 29.04. | Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma | ||
| 29.04. | Client/agency partnerships - a marriage of science and creativity | ||
| 28.04. | Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition | ||
| 28.04. | Roche to boost US footprint with $50bn investment over next five years | ||
| 28.04. | Pfizer's sasanlimab improves event-free survival in phase 3 bladder cancer trial | ||
| 28.04. | Health misinformation: can pharma really have an impact? | ||
| 25.04. | Johnson & Johnson's Tremfya granted EC approval to treat ulcerative colitis in adults | ||
| 25.04. | Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m | ||
| 25.04. | Ipsen's elafibranor shows promise in rare liver disease primary sclerosing cholangitis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .